Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (3)

Trial Status

Completed2
Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05807399Phase 2Recruiting

PanACEA - STEP2C -01

NCT05926466Phase 2Unknown

BTZ-043 Dose Evaluation in Combination and Selection

NCT03959566Phase 2Completed

PanACEA Sutezolid Dose-finding and Combination Evaluation

NCT04044001Phase 1Completed

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

Showing all 4 trials

Research Network

Activity Timeline